Related Experiment Video
Updated: Aug 16, 2025
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Recent advances in anti-coxsackievirus A16 viral drug research
Xiaolan Yuan1, Ziwei Liu1, Li Wan1
1Key Laboratory of Green Chemical Engineering Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430205, PR China.
Insights
Hand, foot, and mouth disease (HFMD) is a common childhood illness. This study reviews Coxsackievirus A16 (CV-A16), a key pathogen in HFMD, and discusses current research on potential antiviral treatments.
Area of Science:
- Virology
- Infectious Diseases
- Pediatrics
Background:
- Hand, foot, and mouth disease (HFMD) is a significant public health concern, particularly in the Asia-Pacific region.
- Enteroviruses are the causative agents of HFMD, with Coxsackievirus A16 (CV-A16) being a prominent pathogen.
- CV-A16 infections can lead to severe neurological complications and mortality in infants and young children.
Purpose of the Study:
- To provide a comprehensive overview of Coxsackievirus A16 (CV-A16).
- To summarize current advancements in the research of anti-CV-A16 therapies.
- To highlight the need for effective clinical interventions against CV-A16.
Main Methods:
- Literature review of viral gene and protein structures.
- Analysis of current pharmaceutical targets for anti-CV-A16 drug development.
- Summary of ongoing research in antiviral strategies.
Main Results:
- Detailed description of CV-A16 viral structure and genetics.
- Identification of potential therapeutic targets for CV-A16.
- Overview of the current landscape of drug research against CV-A16.
Conclusions:
- There is a critical need for effective treatments against CV-A16 due to the lack of complete blocking interventions.
- Ongoing research into pharmaceutical targets and drug development is crucial for combating CV-A16-related HFMD.
- Further investigation into CV-A16's biology and therapeutic strategies is warranted.
Abstract:
Hand, foot and mouth disease, a childhood disorder caused by enteroviruses, is intermittently endemic in the Asia-Pacific region and endangers the lives of many infants and young children. Coxsackievirus A16 (CV-A16) is one of the major pathogens causing hand, foot, and mouth disease on occasion, resulting in catastrophic neurological sequelae and patient death. Currently, no clinical interventions are available that completely block the CV-A16 infection. Therefore, research on anti-CV-A16 treatment continues to be a significant focus of interest. This report provides a detailed background on and an introduction to CV-A16; a description of the viral gene and protein structures and a summary of the current advances in pharmaceutical targets, drug research and other related areas.
